Deisseroth, Nagel and Hegemann win the 2026 medicine Nobel for controlling cells with light

Optogenetics, in Scientific American's one-line definition, is an ability: the control of cells using light and genetics ^[2]. The magazine sorts the prize's past into three groups ^[6][7][8]. That definition does not fit cleanly into any of them.

The first group is discoveries, such as insulin, penicillin, blood groups and the molecular structure of DNA ^[6]. The second is understanding of biological processes, including how neurons work, how malaria spreads and the role of human papillomavirus in cervical cancer ^[7]. The third is treatments, among them in vitro fertilization and the first antibiotic for tuberculosis ^[8].

I think optogenetics is closest to an instrument. What it is worth to medicine depends on the experiments other researchers run with it. The breaking report ^[9] does not say which cells the method has been used on, what those experiments found, or what other work was in contention for the prize.

Counting this year, only the 2023 award among the last four is tied to a medical product ^[13]. Four years is too short a run to call a trend.

Three laureates is above the prize's historical average. Divide Scientific American's count of winners by its count of awards and the result is two per prize ^[10], so this year's split runs one above it ^[11]. The thing this doesn't tell you is whether three-way splits have become more common lately, since the average covers 125 years of awards ^[12].

One detail is unsettled in the report as filed. Its headline gives the second laureate's first name as Georg, and its text gives George ^[5].